TrialInvestigational new drugs2005
Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.
Aimee K Bence et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
29 papers cite it
this papertrialcites it